Obesity’s Public Health Threat; Divorce and Amputation Risk; Home Hormone Tests?

Obesity is the second greatest threat to U.S. public health at the moment, said respondents of a new poll, preceded only by opioids. (Axios)

The Endocrine Society announced its 2024 Laureate Award winners, with the lifetime achievement award going to past president E. Dale Abel, MBBS, DPhil, of UCLA Health in Los Angeles.

In those with diabetes, being divorced was tied with a 67% higher risk of lower limb amputation while being male was linked with a 57% higher risk, according to new research to be presented at the European Association for the Study of Diabetes (EASD) annual meeting in October. Check back here later for MedPage Today‘s coverage of the meeting.

After achieving near 15% weight loss after 46 weeks in a phase II trial, developer Boehringer Ingelheim said it will soon test its investigational glucagon/GLP-1 receptor dual agonist survodutide in three phase III trials.

Direct-to-consumer at-home anti-Mullerian hormone testing companies often boast false claims about predicting fertility, according to a qualitative analysis of 27 websites. (JAMA Network Open)

Considering the relatively good prognosis for patients with low-grade, localized adrenocortical carcinoma, adjuvant mitotane may not be indicated due to added toxicity and the lack of improvement in recurrence-free survival, said researchers in The Lancet Diabetes & Endocrinology.

New weight-loss drugs cost more in the U.S. than abroad, a KFF analysis found.

And the jury’s still out on exactly how GLP-1 receptor agonists work for weight loss. (New York Times)

The FDA warned that certain weight-loss products labeled as containing Nuez de la India appear to actually contain yellow oleander — a poisonous plant that can be fatal when ingested.

Please enable JavaScript to view the

comments powered by Disqus.